Today: 16 April 2026
EOSE stock: Eos Energy slips again premarket after brutal earnings selloff and softer 2026 outlook
27 February 2026
2 mins read

EOSE stock: Eos Energy slips again premarket after brutal earnings selloff and softer 2026 outlook

New York, Feb 27, 2026, 06:49 (EST) — Premarket

• Shares slipped another 2.5% before the bell, adding to Thursday’s steep 39.4% drop.
• Eos delivered record Q4 revenue, yet set its 2026 revenue guidance under what analysts had been looking for.
• Roth Capital lowered its price target, citing execution risk following the Q4 release.

Eos Energy Enterprises shares slipped another 2.5% before the bell Friday, adding to a brutal 39.4% plunge in the previous session as investors dumped the battery maker following its latest quarterly numbers and 2026 guidance. The stock was recently quoted at $6.57. It had settled at $6.74 Thursday, with around 151 million shares changing hands.

This volatility comes as Eos pushes its zinc-based energy storage systems to utilities and commercial buyers—a crowd that hasn’t hesitated to hit the stock for delays or heavy spending. These days, shares react sharply to every update. How things open Friday could signal if investors are buying the post-earnings pivot.

The core of the argument boils down to this: Can Eos actually get those booked orders out the door quickly enough to shrink its losses, or is another capital raise coming? Traders are eyeing the company’s first full-year revenue forecast, trying to decide if it’s the baseline—or just out of reach.

Eos posted its highest-ever fourth-quarter revenue at $58.0 million, with full-year sales climbing to $114.2 million, according to a regulatory filing. Even so, the company logged a net loss to shareholders of $120.5 million for the quarter and $969.6 million for the year—mostly tied to non-cash fair-value and capital-structure effects. Looking ahead, Eos rolled out a 2026 revenue target between $300 million and $400 million. That earlier “substantial doubt” over its ability to keep operating? Gone, the company said, dropping the going-concern warning. CEO Joe Mastrangelo described 2025 as a “structural turning point,” though he acknowledged revenue results fell short of what they’d hoped. SEC

Wall Street zeroed in on the shortfall between the company’s outlook and consensus numbers. Roth Capital’s Chip Moore dropped his price target down to $6 from $12, maintaining a neutral stance. “Execution risks remain high,” Moore wrote, warning the shares may continue reacting to specific events. TheFly’s figures showed consensus revenue for 2026 at $471.26 million; analysts had penciled in a fourth-quarter loss of 84 cents a share, far wider than the 24-cent loss expected. TipRanks

Eos has turned to capital markets for breathing room as it works to scale up production. The company is using convertible notes—debt instruments that may eventually convert into equity, potentially diluting current shareholders. For now, they extend debt maturities and help bolster short-term liquidity.

During the earnings call, Mastrangelo flagged capacity and factory throughput as the areas to watch next, telling analysts the Turtle Creek facility “hit its nameplate capacity” after 2025. He said putting up a new building would “change the game” for both cost and efficiency. Investing.com

The firm is leaning hard on its Indensity product architecture these days, hoping to shift investor focus away from choppy quarterly swings. Management keeps steering attention to the backlog and pipeline, but ultimately, it’s going to come down to deliveries and margin—no amount of slides will change that.

Eos goes up against big lithium-ion names and other storage players, with price cuts landing hard whenever buyers have choices. Eos sells its chemistry on safety and longer storage, but for investors, the whole thing hangs on whether the numbers at the factory add up.

But the downside is clear enough: gross losses are still big, and if production yields slip, supply costs climb, or customers struggle with financing, revenue could get delayed while cash burn keeps running high. Shares could tumble again even without a big headline—something as routine as a delayed shipment or softer margins might be enough.

Stock Market Today

  • NOV Stock Valuation: Contrasting Short-Term Price Moves and Long-Term Momentum
    April 16, 2026, 1:11 AM EDT. NOV (ticker: NOV) has gained 4.6% over one month and 5.5% in three months, yet its 12-month total return stands at a robust 64%. Shares currently trade at $19.02, slightly below a fair value estimate of $20.10, suggesting a modest valuation gap rooted in expectations of future cash flow and execution. Contrastingly, a discounted cash flow (DCF) model values NOV at $29.08, implying a 34.6% undervaluation. The stock's outlook depends on sustained global energy infrastructure investments, especially in LNG and gas processing. However, risks from tariffs, inflation, and pricing pressure could impact margins. Investors are advised to assess these conflicting signals and consider broader opportunities in energy infrastructure sectors as momentum builds steadily over the long term.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 16.04.2026

16 April 2026
LIVEMarkets rolling coverageStarted: April 16, 2026, 12:00 AM EDTUpdated: April 16, 2026, 1:22 AM EDT NOV Stock Valuation: Contrasting Short-Term Price Moves and Long-Term Momentum April 16, 2026, 1:11 AM EDT. NOV (ticker: NOV) has gained 4.6% over one month and 5.5% in three months, yet its 12-month total return stands at a robust 64%. Shares currently trade at $19.02, slightly below a fair value estimate of $20.10, suggesting a modest valuation gap rooted in expectations of future cash flow and execution. Contrastingly, a discounted cash flow (DCF) model values NOV at $29.08, implying a 34.6% undervaluation. The stock's outlook
Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

16 April 2026
Norse Atlantic Airways has canceled all planned summer flights from Los Angeles to London Gatwick, Paris, and Rome, citing surging jet fuel costs. The airline launched a $110 million rights issue, secured a $70 million bridge loan, and withdrew its 2026 outlook. Routes disappeared from booking systems on April 14. Norse had been the only scheduled operator on the Gatwick-Los Angeles route.
S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

16 April 2026
The S&P 500 closed at a record 7,022.95 and the Nasdaq at 24,016.02 on Wednesday, erasing losses from the March selloff tied to the Feb. 28 conflict. Bank of America reported $8.6 billion in first-quarter net income, up 17%, while Morgan Stanley posted record revenue. Talks between Washington and Tehran raised hopes for easing oil supply fears, but Brent crude stayed elevated at $94.93 a barrel.
Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

16 April 2026
China is considering export restrictions on advanced solar-manufacturing equipment to the U.S., potentially affecting Tesla’s plans for new factories, sources told Reuters. Tesla aims to buy $2.9 billion in solar-panel equipment from China and expand U.S. solar production. China produces over 80% of global solar panel components. No final decision has been made, and consultations remain preliminary.
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

15 April 2026
Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
Humana stock jumps 6% as Medicare Advantage enrollment report puts HUM back in focus
Previous Story

Humana stock jumps 6% as Medicare Advantage enrollment report puts HUM back in focus

Intel stock price: INTC set for a tense open after SambaNova AI deal, as chip nerves linger
Next Story

Intel stock price: INTC set for a tense open after SambaNova AI deal, as chip nerves linger

Go toTop